Purdue Pharma Cuts More Than Half of U.S. Sales Staff Amid Opioid Crisis Post author:Sam Post published:February 12, 2018 Post category:BioPharma That announcement is a big change in the way Purdue has aggressively marketed OxyContin in the past. Source: BioSpace You Might Also Like LAM Therapeutics Scores $58 Million and a New Clinical Program in Cancer March 29, 2017 Boehringer CFO Quits After 16 Months on the Job Over Differences in Strategy December 14, 2017 Belgium Biotech Ablynx Files For $150 Million U.S. IPO Right After Phase III Boost October 2, 2017